A phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin mRNA antagonist, administered with or without docetaxel in adult patients with advanced solid tumors or lymphoma
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2011
At a glance
- Drugs Docetaxel; EZN 3042
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 12 Nov 2011 Results from patients with advanced solid tumours presented at the AACR-NCI-EORTC 2011.
- 05 Apr 2011 Results presented at AACR 2011.
- 05 Apr 2011 Status changed from recruiting to completed.